Daniel J. Mitchell

This profile gathers the share dealings of Daniel J. Mitchell across 4 companies, led by Globeimmune Inc, Cardiovascular Systems Inc and Myogen Inc. Over a trading history stretching from 2 February 2006 to 2 May 2017, the count stands at 124 filings.

Both buying and selling appear: 39 purchases worth €977k, against 56 sales worth €430k. The net balance comes to €547k on the buying side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2017: 1 purchase and no sales on the market.

In size, the median ticket on the buying side is €4,162.

The record was last updated on 3 May 2017 with an open-market purchase (€27k) in Oruka Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.